Skip to main content
NCBI home page
Immunology logoLink to Immunology
. 1997 Oct;92(2):166–172. doi: 10.1046/j.1365-2567.1997.d01-2308.x

Modulation in vitro of human natural cytotoxicity, lymphocyte proliferative response to mitogens and cytokine production by essential fatty acids.

P Purasiri 1, A Mckechnie 1, S D Heys 1, O Eremin 1
PMCID: PMC1364054  PMID: 9415022

Abstract

Essential fatty acids (EFA) have been shown in animal studies to have a differential effect on various aspects of immune reactivity. However, there have been few studies in humans. Therefore, we elected to investigate the effects of a variety of EFA [gamma-linolenic acid (GLA), eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)] in vitro on human blood lymphocyte reactivity, cytokine secretion and natural cytotoxicity. The proliferative response to polyclonal mitogens (phytohaemagglutinin, pokeweed mitogen, concanavalin A), as measured by [3H]thymidine incorporation into newly synthesized lymphocytes, was inhibited (P < 0.05) by all EFAs tested, in a dose-dependent manner (3-15 micrograms/ml). The greatest inhibition of proliferation was caused by EPA and DHA. Similarly, EPA, DHA and GLA significantly reduced cytotoxic activity [expressed as lytic units, using 51 chromium-release assays natural killer (NK) (K562 cells) and lymphokine-activated (LAK) (Daudi cells) cells] (P < 0.05) in a concentration-dependent manner (5-50 micrograms/ml), without affecting cell viability. EPA and DHA exhibited greater suppression than GLA. Furthermore, the inhibition of cell proliferation and suppression of natural cytotoxicity was associated with marked decrease in cytokine [interleukin-1 (IL-1), IL-2, tumour necrosis factor-alpha (TNF-alpha) and interferon-gamma (IFN-gamma)] production in vitro. Our findings demonstrate that EFAs (GLA, EPA, DHA) have the potential to inhibit significantly various aspects of human lymphocyte cell-mediated and humoral immune reactivities.

Full text

PDF
166

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anel A., Naval J., González B., Uriel J., Piñeiro A. Fatty acid metabolism in human lymphocytes. II. Activation of fatty acid desaturase-elongase systems during blastic transformation. Biochim Biophys Acta. 1990 Jun 14;1044(3):332–339. doi: 10.1016/0005-2760(90)90077-b. [DOI] [PubMed] [Google Scholar]
  2. Billingham M. E. Cytokines as inflammatory mediators. Br Med Bull. 1987 Apr;43(2):350–370. doi: 10.1093/oxfordjournals.bmb.a072187. [DOI] [PubMed] [Google Scholar]
  3. Bégin M. E., Ells G., Das U. N., Horrobin D. F. Differential killing of human carcinoma cells supplemented with n-3 and n-6 polyunsaturated fatty acids. J Natl Cancer Inst. 1986 Nov;77(5):1053–1062. [PubMed] [Google Scholar]
  4. Calder P. C., Newsholme E. A. Polyunsaturated fatty acids suppress human peripheral blood lymphocyte proliferation and interleukin-2 production. Clin Sci (Lond) 1992 Jun;82(6):695–700. doi: 10.1042/cs0820695. [DOI] [PubMed] [Google Scholar]
  5. Cerottini J. C., Brunner K. T. Cell-mediated cytotoxicity, allograft rejection, and tumor immunity. Adv Immunol. 1974;18:67–132. doi: 10.1016/s0065-2776(08)60308-9. [DOI] [PubMed] [Google Scholar]
  6. Dinarello C. A. Biology of interleukin 1. FASEB J. 1988 Feb;2(2):108–115. [PubMed] [Google Scholar]
  7. Dinarello C. A., Bishai I., Rosenwasser L. J., Coceani F. The influence of lipoxygenase inhibitors on the in vitro production of human leukocytic pyrogen and lymphocyte activating factor (interleukin-1). Int J Immunopharmacol. 1984;6(1):43–50. doi: 10.1016/0192-0561(84)90033-x. [DOI] [PubMed] [Google Scholar]
  8. Endres S., Ghorbani R., Kelley V. E., Georgilis K., Lonnemann G., van der Meer J. W., Cannon J. G., Rogers T. S., Klempner M. S., Weber P. C. The effect of dietary supplementation with n-3 polyunsaturated fatty acids on the synthesis of interleukin-1 and tumor necrosis factor by mononuclear cells. N Engl J Med. 1989 Feb 2;320(5):265–271. doi: 10.1056/NEJM198902023200501. [DOI] [PubMed] [Google Scholar]
  9. Erickson K. L., Adams D. A., McNeill C. J. Dietary lipid modulation of immune responsiveness. Lipids. 1983 Jul;18(7):468–474. doi: 10.1007/BF02535787. [DOI] [PubMed] [Google Scholar]
  10. Erickson K. L. Dietary fat modulation of immune response. Int J Immunopharmacol. 1986;8(6):529–543. doi: 10.1016/0192-0561(86)90023-8. [DOI] [PubMed] [Google Scholar]
  11. Gearing A. J., Thorpe R. The international standard for human interleukin-2. Calibration by international collaborative study. J Immunol Methods. 1988 Nov 10;114(1-2):3–9. doi: 10.1016/0022-1759(88)90145-7. [DOI] [PubMed] [Google Scholar]
  12. Hanna N. The role of natural killer cells in the control of tumor growth and metastasis. Biochim Biophys Acta. 1985;780(3):213–226. doi: 10.1016/0304-419x(85)90004-6. [DOI] [PubMed] [Google Scholar]
  13. Heys S. D., Franks C. R., Eremin O. Interleukin 2 therapy: current role in surgical oncological practice. Br J Surg. 1993 Feb;80(2):155–162. doi: 10.1002/bjs.1800800209. [DOI] [PubMed] [Google Scholar]
  14. Horrobin D. F. The regulation of prostaglandin biosynthesis by the manipulation of essential fatty acid metabolism. Rev Pure Appl Pharmacol Sci. 1983 Oct-Dec;4(4):339–383. [PubMed] [Google Scholar]
  15. Hwang D. Essential fatty acids and immune response. FASEB J. 1989 Jul;3(9):2052–2061. doi: 10.1096/fasebj.3.9.2501132. [DOI] [PubMed] [Google Scholar]
  16. Johnston D. V., Marshall L. A. Dietary fat, prostaglandins and the immune response. Prog Food Nutr Sci. 1984;8(1-2):3–25. [PubMed] [Google Scholar]
  17. Kennedy R. L., Jones T. H. Cytokines in endocrinology: their roles in health and in disease. J Endocrinol. 1991 May;129(2):167–178. doi: 10.1677/joe.0.1290167. [DOI] [PubMed] [Google Scholar]
  18. Kunkel S. L., Chensue S. W. Arachidonic acid metabolites regulate interleukin-1 production. Biochem Biophys Res Commun. 1985 Apr 30;128(2):892–897. doi: 10.1016/0006-291x(85)90130-5. [DOI] [PubMed] [Google Scholar]
  19. Kunkel S. L., Chensue S. W., Phan S. H. Prostaglandins as endogenous mediators of interleukin 1 production. J Immunol. 1986 Jan;136(1):186–192. [PubMed] [Google Scholar]
  20. Lee T. H., Hoover R. L., Williams J. D., Sperling R. I., Ravalese J., 3rd, Spur B. W., Robinson D. R., Corey E. J., Lewis R. A., Austen K. F. Effect of dietary enrichment with eicosapentaenoic and docosahexaenoic acids on in vitro neutrophil and monocyte leukotriene generation and neutrophil function. N Engl J Med. 1985 May 9;312(19):1217–1224. doi: 10.1056/NEJM198505093121903. [DOI] [PubMed] [Google Scholar]
  21. Mazumder A., Rosenberg S. A. Successful immunotherapy of natural killer-resistant established pulmonary melanoma metastases by the intravenous adoptive transfer of syngeneic lymphocytes activated in vitro by interleukin 2. J Exp Med. 1984 Feb 1;159(2):495–507. doi: 10.1084/jem.159.2.495. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Meade C. J., Mertin J. Fatty acids and immunity. Adv Lipid Res. 1978;16:127–165. doi: 10.1016/b978-0-12-024916-9.50008-1. [DOI] [PubMed] [Google Scholar]
  23. Meydani S. N., Endres S., Woods M. M., Goldin B. R., Soo C., Morrill-Labrode A., Dinarello C. A., Gorbach S. L. Oral (n-3) fatty acid supplementation suppresses cytokine production and lymphocyte proliferation: comparison between young and older women. J Nutr. 1991 Apr;121(4):547–555. doi: 10.1093/jn/121.4.547. [DOI] [PubMed] [Google Scholar]
  24. Mizel S. B. The interleukins. FASEB J. 1989 Oct;3(12):2379–2388. doi: 10.1096/fasebj.3.12.2676681. [DOI] [PubMed] [Google Scholar]
  25. Ortaldo J. R., Bonnard G. D., Herberman R. B. Cytotoxic reactivity of human lymphocytes cultured in vitro. J Immunol. 1977 Oct;119(4):1351–1357. [PubMed] [Google Scholar]
  26. Patel P. M., Collins M. K. Cytokine modulation of cell growth and role in tumour therapy. Eur J Cancer. 1992;28(1):298–302. doi: 10.1016/0959-8049(92)90439-9. [DOI] [PubMed] [Google Scholar]
  27. Payan D. G., Goetzl E. J. Specific suppression of human T lymphocyte function by leukotriene B4. J Immunol. 1983 Aug;131(2):551–553. [PubMed] [Google Scholar]
  28. Ramstedt U., Serhan C. N., Lundberg U., Wigzell H., Samuelsson B. Inhibition of human natural killer cell activity by (14R,15S)-14,15-dihydroxy-5Z,8Z,10E,12E- icosatetraenoic acid. Proc Natl Acad Sci U S A. 1984 Nov;81(22):6914–6918. doi: 10.1073/pnas.81.22.6914. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Rola-Pleszczynski M., Gagnon L., Chavaillaz P. A. Immune regulation by leukotriene B4. Ann N Y Acad Sci. 1988;524:218–226. doi: 10.1111/j.1749-6632.1988.tb38545.x. [DOI] [PubMed] [Google Scholar]
  30. Rola-Pleszczynski M., Lemaire I. Leukotrienes augment interleukin 1 production by human monocytes. J Immunol. 1985 Dec;135(6):3958–3961. [PubMed] [Google Scholar]
  31. Rosenberg S. A., Lotze M. T. Cancer immunotherapy using interleukin-2 and interleukin-2-activated lymphocytes. Annu Rev Immunol. 1986;4:681–709. doi: 10.1146/annurev.iy.04.040186.003341. [DOI] [PubMed] [Google Scholar]
  32. Rosenberg S. A., Lotze M. T., Muul L. M., Chang A. E., Avis F. P., Leitman S., Linehan W. M., Robertson C. N., Lee R. E., Rubin J. T. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med. 1987 Apr 9;316(15):889–897. doi: 10.1056/NEJM198704093161501. [DOI] [PubMed] [Google Scholar]
  33. Rosenthal M. D. Fatty acid metabolism of isolated mammalian cells. Prog Lipid Res. 1987;26(2):87–124. doi: 10.1016/0163-7827(87)90009-9. [DOI] [PubMed] [Google Scholar]
  34. Santoli D., Zurier R. B. Prostaglandin E precursor fatty acids inhibit human IL-2 production by a prostaglandin E-independent mechanism. J Immunol. 1989 Aug 15;143(4):1303–1309. [PubMed] [Google Scholar]
  35. Spector A. A., Mathur S. N., Kaduce T. L., Hyman B. T. Lipid nutrition and metabolism of cultured mammalian cells. Prog Lipid Res. 1980;19(3-4):155–186. doi: 10.1016/0163-7827(80)90003-x. [DOI] [PubMed] [Google Scholar]
  36. Strasser T., Fischer S., Weber P. C. Leukotriene B5 is formed in human neutrophils after dietary supplementation with icosapentaenoic acid. Proc Natl Acad Sci U S A. 1985 Mar;82(5):1540–1543. doi: 10.1073/pnas.82.5.1540. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Trinchieri G., Perussia B. Human natural killer cells: biologic and pathologic aspects. Lab Invest. 1984 May;50(5):489–513. [PubMed] [Google Scholar]
  38. Van Meir E., Sawamura Y., Diserens A. C., Hamou M. F., de Tribolet N. Human glioblastoma cells release interleukin 6 in vivo and in vitro. Cancer Res. 1990 Oct 15;50(20):6683–6688. [PubMed] [Google Scholar]
  39. Wu S., Boyer C. M., Whitaker R. S., Berchuck A., Wiener J. R., Weinberg J. B., Bast R. C., Jr Tumor necrosis factor alpha as an autocrine and paracrine growth factor for ovarian cancer: monokine induction of tumor cell proliferation and tumor necrosis factor alpha expression. Cancer Res. 1993 Apr 15;53(8):1939–1944. [PubMed] [Google Scholar]
  40. Zurier R. B. Fatty acids, inflammation and immune responses. Prostaglandins Leukot Essent Fatty Acids. 1993 Jan;48(1):57–62. doi: 10.1016/0952-3278(93)90010-t. [DOI] [PubMed] [Google Scholar]

Articles from Immunology are provided here courtesy of British Society for Immunology

RESOURCES